4 results match your criteria: "Harvard University Kennedy School of Government[Affiliation]"
Site-of-Care Shifts and Payments-A Viable Strategy to Control Health Care Costs?
JAMA Netw Open
August 2024
Harvard University Kennedy School of Government, Cambridge, Massachusetts.
Making Health Care Truly Affordable after Health Care Reform.
J Law Med Ethics
December 2016
Timothy Stoltzfus Jost, J.D., is a member of the National Academy of Medicine and an Emeritus Professor at the Washington and Lee University School of Law. He is a contributing editor at Health Affairs and a consumer representative to the National Association of Insurance Commissioners. He received his Juris Doctor from the University of Chicago (Chicago, IL). Harold A. Pollack, Ph.D., works at the University of Chicago where he is the Helen Ross Professor at the School of Social Service Administration and is an Affiliate Professor in the Biological Sciences Collegiate Division and the Department of Public Health Sciences. He is the Co-Director of the University of Chicago Crime Lab and a committee member of the Center for Health Administration Studies (CHAS) at the University of Chicago. He attended Princeton University (Princeton, NJ) where he received his bachelor's degree and holds master's and doctorate degrees in public policy from the Harvard University Kennedy School of Government (Cambridge, MA).
The Affordable Care Act (ACA) is an essential first step toward making health insurance more affordable for lower and moderate income Americans. It has accomplished historic reductions in the proportion of Americans who are uninsured. The number of Americans reporting delaying medical care for financial reasons has declined by approximately one-third since 2010.
View Article and Find Full Text PDFReturns to Society from Investment in Cancer Research and Development.
Forum Health Econ Policy
June 2016
Celgene Corporation, Summit, NJ, USA.
Background: Since the start of the War on Cancer there have been enormous investments in improving oncology treatment. The return to society generated by this investment is unknown. We estimate the returns generated over the previous four decades and extrapolate future returns from current investment in cancer R&D.
View Article and Find Full Text PDF